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ABSTRACT 22 
 23 
Background:  24 
It is unclear to what extent pre-clinical studies in genetically homogeneous animal models of 25 
amyotrophic lateral sclerosis (ALS), an invariably fatal neurodegenerative disorder, can be 26 
informative of human pathology. The disease modifying effects in animal models of most 27 
therapeutic compounds have not been reproduced in patients. To advance therapeutics in ALS, 28 
we need easily accessible disease biomarkers which can discriminate across the phenotypic 29 
variants observed in ALS patients and can bridge animal and human pathology. Peripheral 30 
blood mononuclear cells alterations reflect the rate of progression of the disease representing 31 
an ideal biological substrate for biomarkers discovery.  32 
Methods: We have applied TMTcalibrator™, a novel tissue-enhanced bio fluid mass 33 
spectrometry technique, to study the plasma proteome in ALS, using peripheral blood 34 
mononuclear cells as tissue calibrator. We have tested slow and fast progressing SOD1G93A 35 
mouse models of ALS at a pre-symptomatic and symptomatic stage in parallel with fast and 36 
slow progressing ALS patients at an early and late stage of the disease. Immunoassays were 37 
used to retest the expression of relevant protein candidates.  38 
 3 
Results: The biological features differentiating fast from slow progressing mouse model 39 
plasma proteomes were different from those identified in human pathology, with only 40 
processes encompassing membrane trafficking with translocation of GLUT4, innate immunity, 41 
acute phase response and cytoskeleton organization showing enrichment in both species. 42 
Biological processes associated with senescence, RNA processing, cell stress and metabolism, 43 
major histocompatibility complex-II linked immune-reactivity and apoptosis (early stage) were 44 
enriched specifically in fast progressing ALS patients. Immunodetection confirmed regulation 45 
of the immunosenescence markers Galectin-3, Integrin beta 3 and Transforming growth factor 46 
beta-1 in plasma from pre-symptomatic and symptomatic transgenic animals while 47 
Apolipoprotein E differential plasma expression provided a good separation between fast and 48 
slow progressing ALS patients.  49 
Conclusions: These findings implicate immunosenescence and metabolism as novel targets 50 
for biomarkers and therapeutic discovery and suggest immunomodulation as an early 51 
intervention. The variance observed in the plasma proteomes may depend on different 52 
biological patterns of disease progression in human and animal model. 53 
 54 
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BACKGROUND 58 
 Amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder, is a clinically 59 
heterogeneous condition where survival can be less than a year or more than a decade from 60 
symptoms onset, making any assessment of treatment response in clinical trials difficult in 61 
absence of reliable estimates of prognosis [1]. A significant diagnostic delay in ALS prevents 62 
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early treatment reducing the prospect of therapeutic success [2]. Mutant superoxide dismutase 63 
1 (SOD1G93A) transgenic mice models of ALS are widely used as surrogates of human 64 
pathology in pre-clinical research. A relatively uniform genetic background and the strictly 65 
controlled environmental and breeding conditions make SOD1G93A transgenic animals ideal 66 
models to investigate the disease pathobiology and the pre-symptomatic disease stage [3, 4].    67 
 68 
Experimental evidence suggests that the rate of disease progression in ALS may be linked to 69 
the immunological response to neuronal degeneration, which is reproduced systemically by 70 
altered blood levels of cytokines, acute phase reactants and by an early down-regulation of 71 
FoxP3-positive T regulatory cells predominantly in patients with a faster disease progression 72 
[5, 6]. In SOD1G93A transgenic mouse models of ALS, symptomatic disease can develop 73 
with a slow and fast progression in C57 and 129Sv genetic backgrounds respectively (here 74 
defined as Sym-SOD1C57 and Sym-SOD1129S). In these SOD1G93A transgenic mice, 75 
impairment of the protein quality control in the spinal cord and the activation of the major 76 
histocompatibility complex I (MHCI) expression in axons and neuromuscular junctions are 77 
considered indices of fast disease progression [7, 8].  78 
 79 
The inflammatory response in ALS co-exists with a state of deranged lipid metabolism and 80 
altered total daily energy expenditure [6, 9, 10], associated also with the effects of genetic 81 
mutations of the TDP-43 and C9orf72 genes linked to familial ALS [11-14]. Importantly, it is 82 
also acknowledged that functionally competent and high energy-demanding motor neurons 83 
are vulnerable to chronic inflammation and changes in metabolism [15-17] while aging, one 84 
of the main risk factors for ALS, may increase neuronal vulnerability with a decline in cell 85 
glucose uptake and mitochondrial energy production [18]. 86 
 87 
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Over 50 randomized controlled clinical trials in ALS have been unsuccessful, despite many 88 
compounds having shown a disease-modifying effect in animal models [19-21]. There is 89 
therefore a critical need to improve translation of pre-clinical results into clinical trial 90 
outcomes in ALS, through the identification of molecular factors driving disease progression 91 
in humans and rodents which can be used for phenotypic stratification across species.  To this 92 
end, a viable strategy is the molecular profiling of accessible biofluids and of Peripheral 93 
Blood Mononuclear Cells (PBMC), central to many aspects of the systemic immunological 94 
reaction to neurodegeneration [22, 23]. TMTcalibrator™, an unbiased proteomics method, is 95 
ideally placed to combine tissue and fluid proteomics in a single experiment, providing 96 
significant gains in sensitivity and a direct link between protein expression in diseased tissue 97 
and in matched fluids [24]. 98 
 99 
In this study, we have used TMTcalibrator™ to investigate biological features which are 100 
regulated in plasma and are also coherently expressed in matched PBMC samples from 101 
pre-symptomatic and symptomatic SOD1G93A transgenic mouse models of ALS with a fast 102 
(129Sv strain) and a slow (C57 strain) progression of the disease. We have used the same 103 
approach to test the plasma/PBMC proteome in fast and slow progressing ALS patients 104 
(defined as ALS-Fast and ALS-Slow), at an early and late stage of the disease. We have 105 
detected an early inflammatory and acute phase response in both human and animal model, 106 
while perturbed metabolism and an overall switch to cellular senescence is seen in fast 107 
progressing human pathology. We found only a partial overlap of the plasma/PBMC 108 
proteome between rodents and humans, suggesting a variability which is disease-stage 109 
dependent.  110 
 111 
METHODS 112 
 6 
Animal models 113 
Female superoxide dismutase 1 (SOD1) transgenic mice with a G93A mutation in a 114 
C57BL/6JOlaHsd (C57SOD1G93A) and in a 129SvHsd (129SvSOD1G93A) genetic 115 
background and wild-type female littermates (defined as WTC57 and WT129Sv) were used in 116 
this study (Jackson Laboratories, B6SJL-TgNSOD-1-SOD1G93A-1Gur). The development of 117 
the symptomatic stage of the disease differed significantly in the two SOD1G93A transgenic 118 
mouse strains, with regards to disease onset and duration [8, 25]. In this study, fast developing 119 
symptomatic SOD1G93A transgenic mice are defined as Sym-SOD1129Sv (129Sv pre-120 
symptomatic mice as Pre-SOD1129Sv), while slow symptomatic progressing mice as Sym-121 
SOD1C57 (C57 pre-symptomatic mice as Pre-SOD1C57). SOD1G93A transgenic animals 122 
expressed 20 copies of the human Gly93Ala SOD1 gene substitution in the C57OlaHsd and 123 
129SvHsd backgrounds for more than 30 and 10 generations respectively. Mice were 124 
maintained in a speciﬁc pathogen-free environment (21°C temperature, 10% relative humidity 125 
in a 12 hour of light/dark cycle) with food/water supplied ad libitum and adaptations for 126 
animals with a substantial motor impairment. Mice of both strains were considered in a 127 
symptomatic stage when they exhibited a 50% decrease in latency of grip strength and a 45% 128 
body weight decline from the peak values in the pre-symptomatic stage [26]. Plasma samples 129 
from Wild type (WT) animals used in the re-test experiments were obtained at the same time 130 
of blood collection from both pre-symptomatic and symptomatic SOD1G93A transgenic 131 
animal models.  132 
 133 
Patient selection  134 
ALS patients and biological samples were selected from the ALS biomarkers study 135 
biorepository (Ethical approval: London and the City Research Ethics Committee 1 136 
09/H0703/27). Exclusion criteria were neuroinflammatory and neurodegenerative 137 
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comorbidities, recent mechanical injuries and/or infections, systemic autoimmune disorders, 138 
cancer, pro-thrombotic states, family history of ALS or frontotemporal dementia (FTD) as well 139 
as known genetic mutation linked to ALS or FTD. The Functional Rating Scale-Revised 140 
(ALSFRS-R; range 1 to 48, with increasing levels of neurological impairment with lower 141 
scores) was used to define the level of neurological impairment, with early ALS corresponding 142 
to a score > 40 and late ALS < 35. Disease progression to last visit (PRL) was calculated as 143 
“48 - ALSFRS-R at the last visit, divided for disease duration from onset to the last visit in 144 
months” (fast ALS progression: PRL>0.7; slow ALS progression: PRL< 0.5)[6] .  145 
 146 
Sample collection, plasma and mononuclear cell extraction and processing   147 
18 ml blood were collected in EDTA tubes and centrifuged at 800g for 10 minutes at room 148 
temperature. Plasma was recovered and centrifuged at 3500rpm for 10 minutes and stored at - 149 
80°C.  Plasma samples were albumin and IgG depleted (ProteoPrep® Immunoaffinity kit). 150 
PBMC were isolated by density-gradient 2,000 rpm centrifugation for 40 minutes at 20°C using 151 
LymphoprepTM (Alere) and subsequently washed in Dulbecco’s phosphate-buffered saline 152 
(Gibco). PBMC pellets were stored at -80°C in a freezing solution (10% DMSO in foetal 153 
bovine serum). After 24 hours, PBMC aliquots were transferred into liquid nitrogen. PBMC 154 
samples were thawed at 37°C and re-suspended in 10 ml warm (37°C) Dulbecco phosphate 155 
buffer. Cell suspension was centrifuged at room temperature and the pellet was re-suspended 156 
in 100 µl of lysis buffer (8 M urea, 75 mM NaCl, 50 mM Tris, pH 8.2, protease inhibitors 157 
cocktail, cOmplete™, Mini Protease Inhibitor Co, Sigma). Blood was collected from mice 158 
cheek and diluted in 3 ml medium (2.5 mM EDTA, 2% FBS in PBS) for PBMC and plasma 159 
fractions isolation as reported above. PBMC samples were lysed, sonicated and stored at -80° 160 
C. 161 
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 162 
In-Solution Tryptic Digest, Tandem mass tag (TMT®) labelling and TMT 163 
calibrator™ 164 
Protein quantification was carried out using a Bradford Protein Assay (Bio Rad). 100 µg (30 165 
µg for mice) protein from depleted plasma and 1 mg (750 µg for mice) from the PBMC pool 166 
were dried down in a vacuum centrifuge (SpeedVac, Thermo Scientific). Following 167 
solubilisation and denaturation in 100 mM Triethylammonium bicarbonate (TEAB)/0.1% 168 
(w/v) SDS), samples were reduced with 1 mM tris (2-carboxyethyl) phosphine 10 (TCEP) at 169 
55 °C for 60 minutes and alkylated with 7.5mM iodoacetamide at room temperature (RT) for 170 
60 minutes. Trypsin (MS grade, Promega) was added at a 1:25 (w/w) ratio to total protein and 171 
incubated at 37°C overnight. Digestion products were labelled with TMT®10plex reagents 172 
(Thermo Scientific) and incubated at RT for 60 minutes. Six of the 10 isobaric TMT® reagents 173 
were used to label individual plasma samples and the total amount of PBMC protein pool was 174 
divided among the remaining 4 TMT channels (the four-point calibrator) comprising 1/21, 175 
4/21, 6/21 and 10/21 total protein respectively. To quench the TMT® reaction, 0.25% 176 
hydroxylamine was added. The samples were then combined to form the analytical 10plex sets, 177 
desalted in RP18 columns and dried under vacuum. The human plasma samples were divided 178 
into four TMT®10plex sets, two for the early and two for the late time point plasma samples. 179 
Each set contained three ALS-Fast and three ALS-Slow plasma samples in combination with 180 
the four-point PBMC pool lysate, used as calibrator. The same experimental design was applied 181 
to the animal model study, where four different TMT®10plex sets were used to compare 24 182 
samples in total. Two TMT®10plex sets included samples from transgenic mice, one for Pre-183 
SOD1129Sv and Pre-SOD1C57, and the other one for Sym-SOD1129Sv and Sym-SOD1C57 184 
(n=3 for each genetic background plus 4 channels in each set for the PBMC calibrator). The 185 
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remaining two TMT®10plex sets included plasma samples from the equivalent Wild type (WT) 186 
animals for both 129Sv and C57genetic backgrounds (n:3 per group), collected at the same 187 
time blood was taken from pre-symptomatic and symptomatic animal (additional file 2, 188 
supplementary fig 1 A, shows sample distribution across TMT®10plexes). 189 
 190 
Strong Cation exchange (SCX) Fractionation and liquid chromatography tandem 191 
mass spectrometry (LC-MS/MS) 192 
Each analytical 10plex sample was reconstituted and loaded onto a Polysulfoethyl-A column 193 
(4.6 × 100mm, 5 µm, 200 Å, PolyLC) attached to a Waters 2695 HPLC. Quantitative analysis 194 
was performed using an Orbitrap Fusion™ Tribrid™ mass spectrometer in positive ion mode 195 
with an EASY nLC1000 system and 50cm EASY-Spray column (all Thermo Scientific). More 196 
details on the SCX and LC-MS/MS methodologies are reported in the additional file 1. 197 
 198 
Mass spectrometry analysis and computational proteomics 199 
All plasma samples and pooled PBMC lysates used as tissue calibrator passed sample quality 200 
control protocols (data not shown) and were divided into four TMT®10plex sets. All mass 201 
spectrometry files were inspected independently and passed internal quality control metrics 202 
(data not shown). Outputs of computational proteomics from the 40 raw data files from each 203 
TMT®10plex study (human and animal model study) were assembled into a single dataset and 204 
processed by Proteome Sciences’ proprietary workflows for TMTcalibratorTM including data 205 
integration (CalDIT), pre-processing and feature selection (FeaST).  Normalised quantitative 206 
data were provided for all plasma peptides channels as a ratio against the calculated mid-point 207 
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value of the PBMC calibrator channels (see additional file 2, supplementary figure 1 describing 208 
the experimental workflow).  209 
Peptide identification and quantification 210 
For each experiment, raw mass spectrometry data files were submitted to Proteome Discoverer 211 
(PD) v1.4 (Thermo Scientific), using the Spectrum Files node. The spectrum selector was set 212 
to its default values while the SEQUEST-HT node was set to search data against the human or 213 
mouse (supplemented with the human SOD1 sequence) FASTA UniProtKB and Swiss-Prot 214 
database respectively. A more detailed description of the peptide identification and 215 
quantification process is reported in additional file 1.  216 
 217 
Data assembly, pre-processing and normalisation 218 
In the first step of the CalDIT workflow, reporter ion intensities were corrected to remove the 219 
contribution of signals from adjacent reporter ion channels. Subsequently, within each mass 220 
spectrometry run, intensity values across the four calibrant channels (129C, 130N, 130C, 131) 221 
were normalised (median-scaling) and, for each peptide spectrum match (PSM), a reference 222 
intensity value was calculated based on the calibrant intensity distribution. This reference value 223 
was then used to calculate Log2-transformed PSM ratio values for each of the experimental 224 
channels, resulting in lower variance between PSM-level quantifications of the same peptide 225 
sequence at different points of the elution profile, or MS runs. To generate peptide expression 226 
(ratio) values, median values were then computed across quantified PSMs of the same peptide 227 
sequence.  228 
In the first step of the FeaST workflow, peptides with more than ~ 35% missing quantitative 229 
values within an experimental group (i.e. ALS-Fast-Early; ALS-Fast-Late; ALS-Slow-Early; 230 
ALS-Slow-Late) were removed from subsequent analysis. Remaining peptides, with values 231 
 11 
below the percentage threshold, were replaced by values imputed using the k-nearest 232 
neighbours (n=2) imputation method, applied to samples within each experimental group. In 233 
order to reduce the batch effect created by the use of multiple TMT®10 plexes, a LIMMA-234 
based batch effect correction procedure was applied (additional file 2, supplementary figure 2), 235 
using a linear model constructed on the TMT® 10plex batch number and TMT® channel and 236 
specifying the experimental groups (PCA before batch effect correction additional file 2, 237 
supplementary figure 2).  For protein-level analysis, the same procedure was applied in a 238 
parallel analysis and, subsequently, expression values were computed by averaging (trimmed 239 
mean, trim factor: 0.2) ratios of all non-phosphorylated peptides which matched uniquely to 240 
the gene identifier.  241 
 242 
Two quality control metrics per sample were calculated: the median (measure of central 243 
tendency) and the inter-quartile range (IQR), measure of scale, using peptide and protein 244 
distributions. A sample was considered as a strong outlier if either QC metric value was more 245 
than three standard deviations from the overall mean. 246 
 247 
Immunoassays  248 
Expression analysis of 5 protein candidates in mouse and human plasma samples was 249 
undertaken by enzyme-linked immunosorbent assay (ELISA) using commercial kits, a 250 
electrochemiluminescence (ECL)-based Meso Scale Discovery (MSD) platform and by 251 
Western blot. Plasma samples were processed, aliquoted and frozen at -80°C within 1 hour 252 
from blood collection, according to standard consensus procedures.  ECL-MSD was used to 253 
quantify Apolipoprotein E (APOE; R-PLEX Antibody Set F212I), Galectine-3 (R-PLEX 254 
Antibody Set F214F) and transforming growth factor beta-1 (TGFB1; U-PLEX kit 255 
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K151XWK), in human and mouse plasma, and Apolipoprotein A1 (ApoA1; R-PLEX Antibody 256 
Set F21PR) in human. A commercial ELISA was used to analyse ITGB3 and Apo A1 in mouse 257 
plasma (Biorbyt orb408222 and Abbexa abx254777 respectively) as well ITGB3 in human 258 
plasma (Biorbyt orb407522). Standards, primary and secondary antibodies, detection range 259 
including lower and upper limits of detection were specified in the manufacturer’s conditions. 260 
Plasma samples from Wild-type (WT) and SOD1G93A transgenic mice (both pre-symptomatic 261 
and symptomatic), from ALS-Fast, ALS-Slow and healthy controls were equally distributed 262 
on each plate and measured in duplicate. Each plate contained a target-specific calibrator: 263 
APOA1 (0-1,000,000pg/ml for human and 7.81-500ng/ml for mouse); APOE (0-264 
200,000pg/ml); Galectin-3 (03,000pg/ml), TGFB1 (0-56,600pg/ml) and ITGB3 (125-8000 265 
pg/ml for human 62.5-4000pg/ml for mice). 266 
For Western blot analysis of ITGB3, 40 µg of albumin-depleted proteins were diluted in 267 
Laemmli buffer and loaded onto 10% acrylamide gels. After electrophoresis, proteins were 268 
transferred onto nitrocellulose membranes and blocked with Tris buffered saline 0.1% Tween 269 
(TBS-T) containing 5% non-fat dry milk powder and -20 for 1h at room temperature. 270 
Membranes were then incubated overnight with rabbit anti-Integrin β3 antibody 1:1000 271 
(Integrin β3, D7X3P XP® Rabbit mAb #13166. Cell Signaling Technology, Inc.) and with 272 
anti-Galectin-3 antibody (Mouse monoclonal Galectin 3 ab2785, Abcam Ltd.) in TBS-T 273 
(0.1%) containing 5% bovine serum albumin (BSA) and further incubated with horseradish 274 
peroxidase (HRP)-conjugated swine anti-rabbit 1:2500 (Dako) as secondary antibody in TBS-275 
T (0.1%) containing 5% BSA. Enhanced chemiluminescence (ECL kit; GE Healthcare), the 276 
ChemiDoc XRS+ imaging system and the image lab 5.2.1 (Bio-Rad) software were used for 277 
signal detection acquisition and analysis.  278 
 279 
 13 
Statistical analysis and data mining 280 
All statistical methods applied for the proteomic data analysis were performed using an in-281 
house workflow called FeaST, developed in R statistical programming environment. Principal 282 
component analysis (PCA) score and loading plots were generated to study the variance 283 
structure of the data sets, indicating technical and biological factors and the influence of each 284 
step in the data pre-processing and normalisation workflow. Multifactorial linear modelling 285 
(LIMMA) was applied to determine significantly regulated features (peptides or proteins), 286 
using the following linear model: logRatio ~ Class + Age + Stage + Group (ALS/Control). 287 
Log2 fold changes (logFC) and p-values were calculated for all peptides and proteins that 288 
passed the filtering criteria described (above). The significance criterion α was standardly set 289 
to 0.05 to consider a feature as “regulated”. Multiple testing was performed using a Benjamini-290 
Hochberg correction.  291 
 292 
Proteome Sciences’ proprietary workflows for functional analysis (FAT) were used to identify 293 
differences among phenotypic variants in biological processes extracted from plasma 294 
proteomes. Significance of enrichment was evaluated based on the results of Fisher’s Exact 295 
Test and multiple test corrections were applied (Benjamini-Hochberg). Functional terms used 296 
in this analysis included Gene Ontology Biological Processes and Reactome Pathways. Human 297 
and mouse-specific annotations were extracted from publicly-available data repositories. A 298 
minimum of two matched gene names was required and terms were considered significant. for 299 
a 3-group comparison.  300 
 301 
For the immunoassay data, statistical analysis was performed using GraphPad Prism 6. 302 
Continuous variables were presented in median (interquartile range) and nonparametric 303 
analysis for group comparisons (with Dunn’s multiple comparisons test) as well as correlation 304 
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analysis were applied. We used log rank analysis (Mantel-Cox test) to compare survival (fixed 305 
date was used to censor data for survival analysis).  Receiver operating characteristic curve 306 
analysis was used to assess assay sensitivity/specificity and diagnostic performance. A p value 307 
of less than 0.05 was considered statistically significant. 308 
 309 
We have used a RNA-Seq transcriptome and splicing database of glia, neurons and vascular 310 
cells of the cerebral cortex to look at cell type-specific expression in the central nervous system 311 
(CNS) of Galectin-3, TGFb1 and ITGB3 312 
(https://web.stanford.edu/group/barres_lab/brain_rnaseq.html). 313 
 314 
RESULTS  315 
Patients and controls 316 
17 patients with a diagnosis of possible, probable, laboratory-supported and definite ALS 317 
according to the El Escorial criteria [27] were enrolled in the discovery study (demographic 318 
and clinical features reported in Table 1A, B). Plasma samples from 12 of these, including six 319 
ALS-Fast (progression rate to last visit (PRL) >0.7; male/female ratio 3/3, average age at 320 
disease onset 61.7, 48-67; average disease duration to death or last visit 20.5 months (11-32)) 321 
and six with a slow rate of progression (PRL<0.5; 5 male/1 female, average age at disease onset 322 
58.1, 35-71; average disease duration to death or last visit 107 months (97, 254)) were included 323 
in the exploratory proteomics as analytical samples, while PBMC samples isolated from blood 324 
donated by the remaining five patients were used in the tissue calibrant channels (PRL range: 325 
0.023 – 2.5; three male / two female, average age at disease onset 65.8, 57-68), Table 1).  326 
 327 
 Blood samples from an additional cohort of 47 ALS patients, including 24 ALS-Fast and 23 328 
ALS-Slow, and 29 healthy age and gender-matched controls were used to re-test plasma 329 
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expression of selected protein candidates using immunodetection. The average age of disease 330 
onset among the ALS sub-groups was comparable to the average age of sampling in the healthy 331 
control group (Table 1). The most common genetic mutations linked to familial ALS were 332 
excluded and all ALS patients had plasma CRP and ferritin levels within normal limits at the 333 
time of sampling (normal values: CRP < 5 mg/L; ferritin 10 - 160 μg/L) [6].   334 
 335 
 336 
  337 
  338 
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A.    DISCOVERY EXPERIMENT: ALS PLASMA SAMPLES 
ALS 
 type  
ALSFRS
-R 
 early 
ALSFRS-R  
 late 
Gender 
Age at 
onset 
(years) 
PRL 
Time from 
onset to 
death or 
last visit 
(months) 
Time 
from 
onset to 
first 
sample 
(months) 
Time 
between 
first and 
last 
sample 
(months) 
Site of disease 
onset          
  limb/ bubar M/F 
  
   Slow (n:6) 
43  
(41- 45) 
31.5 
 (27-35) 
5M / 1F 
58.1 (35-
71) 
0.25  
(0.1 – 
0.4) 
107  
(97, 254) 
76  
(30-192) 
58 
 (48-69) 
4 limb /2 bulbar 
Fast  
(n:6) 
43.8 
 (41-46) 
28.6  
(22-35) 
3M / 3F 
61.3 (48-
67) 
1.5 (1-
1.9) 
20.5 (11-32) 
10.2 
 (5-19) 
13.8 (7-
22) 
3 limb /3 bulbar 
B.     DISCOVERY EXPERIMENT: ALS PBMC SAMPLE TO FORM THE REFERENCE POOL 
ALS  
Pool 
ALSRS-R 
Gender  
 
M/F 
Age at 
onset 
(years) 
PRL 
Time from 
onset to 
death or 
last visit 
(months) 
Time from onset to 
sampling (months) 
Site of disease 
onset       limb/ 
bubar 
Slow(3) 
Fast (2) 31  
(22-42) 
3M /2 F 
65.8 (57-
68) 
0.8 
 (0.02–
2.5) 
64.6 
 (8-120) 
19  
(7 – 44) 
3 limb /2 bulbar 
n:5 
C.    RE-TEST EXPERIMENT: ALS PLASMA SAMPLES 
ALS type ALSRS-R 
Gender 
M/F 
 
 
Age at 
onset 
(years) 
PRL 
Time from 
onset to 
death or 
last visit 
(months) 
Time from onset to 
sampling (months) 
Site of disease 
onset           
limb/ bubar 
Slow 39  
(18-47) 
18M / 5F 
65.25 
(37-86.9) 
0.216 
(0.03 – 
0.47) 
120.4 
 (28-335.2) 
62.8 
 (7 -248.8) 
15 limb /8 
bulbar (n: 23) 
Fast 33 
 (13-43) 
8M / 16F 
62.8 
(34.8-
82.4) 
1.48 
(0.74 – 
3.6) 
28.1  
(5 – 50) 
14.8 
 (2.8 – 29.8) 
13 limb /11 
bulbar (n: 24) 
D.    RE-TEST EXPERIMENT: HEALTHY CONTROLS PLASMA SAMPLES 
n:  29 
Gender  M/F Age at sampling (years) 
8M  / 17F 60.9 (50.8 – 73) 
  340 
 341 
 342 
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 343 
 344 
Table 1. Demographics and clinical characteristics of ALS (A,B,C) and healthy control 345 
(D) individuals included in the discovery proteomics (A, B) and in the re-test 346 
immunoassays (C, D). 347 
The ALS functional rating scale revised (ALSFRS-R; 1 to 48, higher level of neurological 348 
disability with lower score) was used to define early (ALSFRS-R ≥ 40) and late (ALSFRS-R 349 
≤ 35) time points in the ALS cohort used for the discovery experiment. ALS patients were 350 
stratified according to disease progression rate to last visit (PRL: 48 minus the ALSFRS-R 351 
score at the last visit, divided per disease duration from onset in months) in slow (PRL<0.5) 352 
and fast (PRL>0.7). PBMC samples were extracted from blood taken from 5 ALS patients with 353 
a variable rate of disease progression (B). Age at onset and gender for both patients and healthy 354 
matched controls are also reported. All individuals belonged to the same ethnic group 355 
(Caucasian; except for one patients who was of Asian ethnicity). Duration of the disease from 356 
onset of first symptoms (e.g. weakness or speech impairment) to both sampling time and 357 
death/last visit is reported. For each sub-group, values are reported as mean (average). 358 
 359 
Exploratory analysis using the Feature Selection Tool (FeaST) 360 
Differentially regulated plasma protein signatures across the four phenotypic variants were 361 
analysed using principal component analysis (PCA), as illustrated in Fig. 1A. The strongest 362 
driver of variance in the data matrix was stage of disease (early vs. late), which was captured 363 
along the first principal component (Fig. 1A: x-axis) and accounted for approximately 36% of 364 
total variance. The rate of disease progression was defined by the second principal component 365 
(Fig. 1A: y-axis) and accounted for 15% of total variance (Fig. 1 B, C and D). 366 
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 367 
Functional analysis 368 
Proteome Sciences’ proprietary tool for functional analysis (FAT) was used to identify 369 
significantly enriched pathways and biological processes in the human and mouse proteomics 370 
data.  A cross-sectional analysis was undertaken at the early (Fig. 2) and late (additional file 2; 371 
supplementary Table 1,1) time points individually using fast vs slow progressing ALS patients 372 
as terms of comparison. Fast and slow ALS phenotypic variants were also analysed separately 373 
in a longitudinal study, comparing early and late time points (additional file 2; supplementary 374 
Table 1, (2-3)). The same analytical approach was used to process data from pre-symptomatic 375 
and symptomatic fast and slow progressing SOD1G93A transgenic animal models (additional 376 
file 2, supplementary Table 1(2-7): cross-sectional and longitudinal analysis; additional file 2 377 
supplementary Table 4: cross-sectional analysis between SOD1G93A transgenic animals and 378 
Wild type littermates )  379 
 380 
Pathway enrichment  381 
To avoid redundancy, only those pathways with the highest enrichment values were shown 382 
when multiple closely related pathways were identified by FAT. The list of selected pathways 383 
is presented in descending order of statistical significance (Fig. 2). In the early stage (Fig. 2A), 384 
the strongest differential expression between fast and slow progressing ALS patients was 385 
related to proteins involved in ER to Golgi anterograde and retrograde transport, programmed 386 
cell death, the immune response linked to MHCII antigen presentation and to pathogenic 387 
Escherichia Coli infection. Pathways found to be regulated in both late stage and earlier time 388 
point plasma samples included cell cycle (mitosis), apoptosis, protein degradation, post-389 
translational modifications and folding, parkin-ubiquitin proteasomal system, organelle 390 
maintenance and membrane transport linked pathways (organelle biogenesis and maintenance, 391 
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phagosome, and translocation of glucose transporter 4 (GLUT4) to the plasma membrane; Fig. 392 
2B). Pathways showing significant enrichment only at the later time point included cellular 393 
responses to stress, senescence, vesicular transport, RHO GTPases, RNA regulatory and 394 
metabolic processes (Fig. 2C).  395 
 396 
When the slow and fast progressing ALS patients were analysed separately and longitudinally 397 
(Fig. 3), the most enriched pathways in slow progressors (Fig. 3A) included DNA damage and 398 
telomere stress induced senescence, inflammation and metabolism. In fast progressing ALS 399 
patients (Fig. 3C), changes in signal transduction and parkin-ubiquitin proteasomal system 400 
pathways were among the most enriched, followed by a cluster of five different pathways 401 
sharing a role in the immune response, RNA regulation and protein transport. Notably, in 402 
common with the cross-sectional study, the longitudinal analysis identified regulation of 403 
proteins involved in cell cycle and signalling, Rho GTPase, membrane trafficking, organelle 404 
mediated transport and translocation of GLUT4 to the plasma membrane (Fig. 3 B).  405 
 406 
Gene Ontology (GO) biological processes:  407 
In the cross-sectional study, cytoskeleton organization was found enriched in both early and 408 
late time points while phagocytosis, epidermis development, membrane organization, innate 409 
immune response, ageing and cell division were among the most enriched biological processes 410 
only in the early time point. In the late time point, regulation of endopeptidase activity was the 411 
top enriched term along with fibrinolysis and proteolysis (additional file 2, supplementary Fig. 412 
3). 413 
 414 
In the longitudinal study and in the fast progressing ALS patients, proteins involved in 415 
cytoskeletal organization, folding and stabilization, cell adhesion, negative regulation of 416 
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endopeptidase activity, innate immune response and substantia nigra development were within 417 
the most significantly enriched biological features (additional file 2, supplementary Fig. 4B). 418 
The analysis of the early versus late time points in the slow progressing patients did not show 419 
any significantly enriched biological process. 420 
 421 
Regulated protein candidates:  422 
The early disease time point was chosen as the source of most informative differentially 423 
expressed plasma protein candidates when comparing ALS-Fast versus ALS-Slow (Table 2; 424 
proteins containing two or more peptides shown in a top-down order of fold-changes). 425 
Additional file 2, table 1 shows the most regulated proteins comparing fast versus slow ALS 426 
patients in late disease (1), early versus late time points in both fast (2) and Slow (3)  427 
progressing ALS patients, as well as those identified in the same cross-sectional (4-5) and 428 
longitudinal (6-7) experiment in animal models. The most regulated proteins emerging from 429 
the comparison of pre-symptomatic and symptomatic SOD1G93A transgenic mice with their 430 
related genetic back-ground WT littermates are reported in additional file 2, table 3. 431 
(For reasons of space and length of the table, Table 3 has been included further down in the 432 
paper) 433 
 434 
Plasma proteomic profile in fast vs slow SOD1 G93A mouse models of ALS and 435 
comparability with human pathology 436 
Functional analysis for enriched pathways and biological processes (GO terms) in the plasma 437 
proteome from the ALS animal models was performed in the same way as for human cases 438 
(additional file 2. Supplementary Table 2). Enriched features were compared with those seen 439 
in the human arm of the study. There was only a partial overlap in enriched pathways between 440 
the human and mouse proteome changes comparing data from the different time points in the 441 
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two species.  Chaperonin mediated protein folding and mitotic processes (pre-symptomatic 442 
mouse model, early and late human ALS; Fig. 4A); RHO GTPase activators of IQGAPs 443 
(symptomatic mouse model, late human ALS) and apoptosis, anchoring of the basal body to 444 
the plasma membrane and AURKA Activation by TPX2 (symptomatic mouse model, early 445 
human ALS) (Fig. 4C) were among the pathways shared by human and mouse ALS. 446 
 447 
However, four pathways; assembly of the primary cilium, organelle biogenesis and 448 
maintenance, regulation of PLK1 Activity at G2/M transition and translocation of GLUT4 to 449 
the plasma membrane were found enriched in both animal models and human disease at all 450 
stages considered (Fig. 4A/ 4C). 451 
 452 
With regards to biological processes, cytoskeleton organization was the only feature enriched 453 
when comparing fast versus slow plasma proteomes from animal and human at the early and 454 
late time points (Fig. 4B/ 4D). The acute-phase response GO term was consistently enriched in 455 
the pre-symptomatic and symptomatic mouse proteome, but only enriched in the late stage of 456 
human disease. The dysregulation of proteolysis pathway was observed only at the late stage 457 
in both species. Phagocytosis engulfment was shared between the human early and the 458 
symptomatic mouse time points (Fig. 4D). 459 
 460 
Immunodetection studies 461 
Using immunodetection, we have re-tested the plasma expression of protein candidates 462 
belonging to the regulated pathways identified by plasma TMT proteomic analysis in 463 
SOD1G93A transgenic mice and in ALS patients, including metabolic processes (APOE, 464 
APOA1), acute response, inflammation and cell senescence (ITGB3, Galectin-3, TGFB1). 465 
These proteins appear also as regulated in the proteomic analysis comparing WT and 466 
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SOD1G93A transgenic mice in both genetic back-grounds (additional file 2, Supplementary 467 
Table 5). The re-test experiment was performed using plasma samples from WT129Sv, Pre-468 
SOD1129Sv, Sym-SOD1129Sv, WTC57, Pre-SOD1C57 and Sym-SOD1C57 mice (n:36, 6 469 
per sub-group) as well as from ALS patients of the discovery cohort (n:12), re-test cohort (n: 470 
47) and from healthy controls (n: 29; Table 1). 471 
 472 
SOD1G93A transgenic mice: ITGB3 was significantly up-regulated in plasma from pre-473 
symptomatic SOD1G93A transgenic mice of both fast (129S) and slow (C57) genetic 474 
backgrounds compared to both WT and symptomatic mice (Figure 5 A2; Pre-SOD1129Sv p= 475 
0.003, Pre-SOD157 p: 0.020). Within the same genotypes, ITGB3 expression decreased 476 
significantly in symptomatic SOD1G93A transgenic mice compared to pre-symptomatic 477 
(Sym-SOD1C57 p: 0.013; Sym-SOD1129S p: 0.039; Figure 5A). Galectin-3 was down-478 
regulated in plasma from pre-symptomatic and symptomatic SOD1G93A transgenic mice with 479 
fast genetic background compared to their WT littermates (Pre-SOD1129Sv p: 0.009; Sym-480 
SOD1129Sv p: 0.004; Figure 5A1), but not in the slow progressing genetic background (Figure 481 
5A1). TGFB1 plasma expression increased significantly in pre-symptomatic and symptomatic 482 
slow SOD1G93A transgenic mice compared to their WT littermates (Figure 5 A2: Pre-SOD157 483 
p: 0.013; Sym-SOD1C57 p: 0.001). Conversely, TGFB1 was down-regulated in pre-484 
symptomatic and symptomatic fast SOD1G93A transgenic mice compared to their WT 485 
littermates (Pre-SOD1129Sv p= 0.039; Sym-SOD1129S p: 0.039). There was no statistically 486 
significant change of APOE and APOA1 plasma expression between WT and SOD1G93A 487 
transgenic mice of both genetic backgrounds (data not shown). For all 5 protein candidates, 488 
immunodetection supported the same pattern of expression found in proteomics.  489 
 490 
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Analysis of RNA expression of Galectin-3, TGFB1 and ITGB3 in a range of cortical cells [28] 491 
showed predominant microglia expression for all three proteins (Figure 5; B, B1, B2 - 492 
https://web.stanford.edu/group/barres_lab/brain_rnaseq.html). 493 
 494 
ALS patients: APOE was up-regulated in plasma from ALS-Fast compared to ALS-Slow and 495 
healthy controls (p: 0.035 and p: 0.041 respectively; Figure 5C). Regression analysis showed 496 
a correlation between APOE plasma levels and PRL (p= 0.041; Figure 5C1). Kaplan Mayer 497 
analysis identified reduced survival in the higher APOE tertile compared to middle and lower 498 
tertiles (p: 0.0156; Figure 4A2) while diagnostic performance by ROC analysis showed APOE 499 
levels separate ALS-Fast from ALS-Slow (Area: 0.6759; Std. Error: 0.07162; p: 0.0204). 500 
APOE analysis in plasma from the discovery cohort (n:12) showed a trend of over-expression 501 
in ALS-fast compared to ALS slow which did not reach significance (data not shown; p: 0.069). 502 
There was no statistically significant regulation of Galectine-3, TGFb1, ApoA1 and ITGB3 503 
plasma levels at group analysis comparing healthy controls to ALS-FAST and ALS-Slow in 504 
both discovery and re-test cohorts, although a trend of up-regulation in ALS-Fast compared to 505 
ALS-Slow was seen in both cohorts for these protein candidates (data not shown).  506 
 507 
ITGB3 and Galectin-3 WB analysis was performed on plasma samples from the discovery and 508 
re-test cohort, including ALS-Fast (n: 12), ALS-Slow (n:12) and healthy controls (n:10).  WB 509 
showed a trend of up-regulation for both Galectin-3 and ITGB3 in ALS-Fast compared to ALS-510 
slow which was not significant (data not shown). These results are in line but not in complete 511 
agreement with the level of differential regulation seen in the proteomic experiment of the early 512 
and late time points (ITGB3 adjusted p value: 0.001111; Galectin adjusted p value: 0.002369; 513 
Table 2, additional file 2 supplementary Table 1). 514 
 515 
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DISCUSSION 516 
This study has three unique aspects: 1) a novel quantitative proteomics approach which 517 
combines tissue and fluid in a single experiment using TMT® labelling and liquid 518 
chromatography combined to mass spectrometry, 2) the use of PBMC, peripheral reporters of 519 
central neuro-inflammation [29] as source tissue for plasma biomarker identification and 3) the 520 
study of two species (human, mouse) with a comparable phenotypic heterogeneity of the 521 
disease. 522 
 523 
We have observed that the rate of ALS progression, and above all the disease stage, are linked 524 
to substantial changes in the abundance of a wide range of plasma proteins. In ALS patients 525 
and animal models, regulated plasma proteins support a range of inflammatory events and 526 
metabolic modifications, while senescence-related alterations are mostly seen with the disease 527 
progression in the human ALS proteome. Studying similar phenotypic variants in mouse 528 
models and patients with ALS, we have identified only a partial overlap in the overall plasma 529 
proteomes acquired in time points which may not necessarily be comparable in the natural 530 
history of the disease in humans and rodents.  Furthermore, the monogenetic driver of disease 531 
in an inbred animal model may only partially reflect the pathological processes of adaptation 532 
seen in sporadic human disease, explaining this discrepancy. It is nevertheless encouraging that 533 
we could dissect common features that could be developed as translational biomarkers to bridge 534 
pre-clinical and human studies.  535 
The cross-sectional proteomic studies in human and animals were based on a relatively small 536 
sample size. The risk of obtaining non-specific biological signals was mitigated by the 537 
inclusion of phenotypic variants and disease time points to test the longitudinal profile of the 538 
disease, while a re-test experiment in larger cohorts of WT and transgenic animals as well as 539 
of ALS patients and healthy controls, helped to confirm the regulation of relevant protein 540 
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candidates observed using proteomics, particularly in mouse model.  Further investigation of 541 
the regulated immuno-metabolic and senescence pathways showed how plasma expression of 542 
APOE differentiates ALS patients based on rate of disease progression, while the study of other 543 
biomarkers like ITGB3, Galectin-3 and TGFB1 confirmed the pattern of regulation across WT 544 
and SOD1G93A transgenic animal models seen in the proteomic experiment. The re-test study 545 
by immunodetection did not show the same degree of regulation for ITG3, Galectin-3 and 546 
TGFB1 shown in ALS-Fast compared to ALS-Slow using deep proteomics. This can be 547 
explained by the small sample size of the discovery cohort used in the proteomic experiment 548 
and by the concomitant high phenotypic (and genetic) variability of the disease in human. MS 549 
and antibody-based detection techniques have also different analytical sensitivity and 550 
specificity, which could also depend on the pre-analytical albumin depletion utilized in 551 
proteomics but not in ELISA, as albumin’s chaperoning and protein-binding activity may affect 552 
the abundance of specific proteins [30]. In the more homogeneous animal models of ALS, 553 
proteomic and immunodetection provided comparable results.   554 
 555 
The plasma/PBMC proteome as a reporter of disease progression in human ALS  556 
PCA indicates that differences in the plasma proteome are more significant between early and 557 
late stages of disease, independent of speed of progression (Fig. 1). The selection of ALS 558 
patients in an “early” disease stage is complicated by unavoidable diagnostic delays and by 559 
poor detection of early signs of “phenoconversion” in asymptomatic individuals. Therefore, in 560 
our study, participants were enrolled and sampled at or shortly after diagnosis, and re-sampled 561 
after an interval of 6 to 24 and of 48 to 56 months for fast and slow progressing ALS patients 562 
respectively (fast and slow ALS patients had comparable ALSFRS-R at the late stage). The 563 
change of the plasma proteomic profile in this time-frame includes the early activation of the 564 
innate immune response (MCH II signalling), initiation of apoptosis and dysfunction of the 565 
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proteasome systems which only partially overlap with the pre-symptomatic mouse plasma 566 
proteome, while later alterations related to metabolism and glucogenesis as well as RHO 567 
GTPase activation are in common with the animal model proteomic (Fig. 2). In our study, RHO 568 
GTPase activity is closely linked to a marked regulation of the cytoskeletal proteins 569 
organization in both species. RHO GTPase binding to plasma membrane-associated actin 570 
cytoskeleton is fundamental to maintain cell-cell and/or cell extracellular matrix (ECM) 571 
adhesion [31]. The early immune response activation in our plasma proteome endorses 572 
previous reports of a systemic inflammatory response in ALS, involving 573 
monocyte/macrophages and a decrease of peripheral T-regulatory cells (Treg) particularly in 574 
fast progressing ALS patients, but may also relate to auto-immune disorders which are co-575 
morbid or precede ALS as previously reported [5, 17, 32-34]. However, none of the cases in 576 
study had such a history and their blood levels of acute phase reactants, including CRP and 577 
ferritin, were within normal limits.  578 
 579 
The prominent expression of proteins involved in the translocation of GLUT4 to the plasma 580 
membrane observed in all disease stages under investigation in human and mice, suggests an 581 
altered glucose uptake from the blood-stream and a dysmetabolic state (Fig. 2). Lactate, a by-582 
product of cell metabolism which has been reported as raised in blood and CSF from ALS 583 
patients, is critically involved in glucose utilization for energy production [35-37]. Recently, it 584 
has been proposed that the adenosine triphosphate (ATP)-dependent lactate flow between 585 
muscle and neurons at the neuromuscular junction (NMJ) may become disrupted in ALS [38]. 586 
Extracellular lactate has been shown to cause T cell entrapment at sites of inflammation by 587 
inhibition of CD4+ and CD8+ T cells motility, inducing chronic inflammation and a switch of 588 
CD4+ T helper cells to a Th17 phenotype with the release of pro-inflammatory cytokines [39]. 589 
Hence lactate may facilitate chronic inflammation, a key feature of neurodegeneration, while 590 
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causing NMJ disruption and motor neuron death. Lactate dyscrasia and translocation of 591 
GLUT4 to plasma membrane have also been reported to interfere with muscle contraction by 592 
loss of GTPase activity [40-44]. The altered GLUT4 translocation and lactate discrasia are 593 
among those features potentially bridging human to animal pathology, representing a 594 
biologically plausible biomarker and treatment target in ALS. 595 
 596 
Inflammation, cell senescence and microglial biomarkers in ALS across species 597 
When the differential plasma proteomic profiles of pre-symptomatic and symptomatic 598 
transgenic animals were compared to early and late ALS cases, we found inter-species 599 
commonalities which included, among others, changes in the acute phase and innate immune 600 
responses, protein folding and GTPase Rho signaling (Figure 5). Further analysis of 601 
differentially regulated features in our study pointed to microglia activation: 1) the early up-602 
regulation of proteins involved in apoptosis, phagocytosis and of the proteasome system 603 
reflecting microglia/macrophage activation which leads to removal of cellular debris and 604 
protein aggregates by phagocytosis [45] and 2) ITGB3, Galctin-3 and TGFB1 are selective 605 
brain microglia markers, according to a  large RNA-Seq transcriptome and splicing database 606 
of glia, neurons, and vascular cells of the cerebral cortex 607 
(https://web.stanford.edu/group/barres_lab/brain_error_3.html; Figure 5, B,B1,B2). 608 
 609 
Integrins, Galectin-3 and TGFB1 have been implicated in different biological processes 610 
including angiogenesis, fibrosis and wound healing [46, 47]. These proteins are also central to 611 
the development of the acute phase response leading to chronic tissue injury [48], a molecular 612 
feature shared by animal and human ALS plasma proteomes.  Critically, ITGB3 has been 613 
shown to be a key factor in cell senescence and in the interplay between membrane and ECM 614 
through a molecular cascade that includes activation of TGFB1 [49]. Our study also show 615 
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activation of telomere stress induced senescence with disease progression, implicating ITGB3 616 
and TGB1 further in replicative senescence, where telomere length becomes fundamental in 617 
loss of cellular homeostasis observed with aging [50]. Astrocyte over-expression of 618 
TGFB1accelerates disease progression in ALS mice [51]. ALS skeletal muscle and plasma also 619 
show enhanced TGFB1signaling, which can lead to muscle fibrosis [52, 53]. The up-regulation 620 
of ITGB3 and TGFB1adds to our previous finding of increased levels of pro-inflammatory 621 
cytokines like IL-6 in plasma from ALS patients, a concerted response described as 622 
senescence-associated secretory phenotype [6, 54-56].  623 
 624 
 625 
ALS: choosing the right therapeutic target and timing for intervention 626 
Any novel treatment strategy for ALS will have to be tested in a more personalized approach, 627 
using biomarkers and genetics for clinical stratification [57]. In humans, the lack of any mean 628 
of accurate prognostication makes ALS clinical heterogeneity the main obstacle to the 629 
development of effective treatments [32]. Conversely, in the relatively homogeneous SOD1 630 
animal models of ALS, phenotypic variations depend only on expression levels of mutant 631 
SOD1, gender,  genetic background and possibly on breeding conditions, all features that can 632 
be manipulated in a controlled experimental setting [58].   633 
 634 
Our study has shown a convergence between species in molecular mechanisms centered around 635 
regulation of the immune response and of cell metabolism. These shared regulated pathways 636 
support the potential for early immune-modulatory strategies, including the use of anti-637 
inflammatory compounds, stem-cell based immune-effective treatment or protein kinase 638 
inhibitors, used to stem microglia-mediated neuroinflammation [21, 59, 60]. While fighting 639 
this innate immune response as early as possible may be plausible, it is worth considering that 640 
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macrophages at this stage and potentially throughout the disease course clear debris from cells 641 
undergoing degeneration. This “beneficial” inflammatory response may later shift towards a 642 
chronic and harmful process [6, 45, 61-65]. Therefore, timing of immunomodulation in ALS 643 
is crucial and interventions must aim at the window of therapeutic opportunity to arrest any 644 
development to chronic inflammation, which is an integral part of cell senescence and of the 645 
SASP response. Inducers of heat shock response have been shown to efficiently inhibit and 646 
reduce chronic inflammation in obesity and the same therapeutic paradigm may be relevant in 647 
neuroinflammation [66]. 648 
 649 
Our findings support also treatment strategies which target the enzymatic chain of glucose 650 
metabolism leading to the production of lactate, based on the combination of drugs that inhibit 651 
lactate accumulation at the NMJ and its effect in reducing T-cell migratory capabilities, 652 
enhancing respiratory chain function, and/or promoting re-innervation [38]. Interestingly, 653 
nutritional supplements acting at the interface between inflammation and metabolism have 654 
been shown to dampen the inflammatory environment. For example, omega-3 essential fatty 655 
acids decrease the levels of IL-1, IL-6, TNFα and CRP [67] and improve cognitive function in 656 
aged mice [68].  657 
 658 
CONCLUSIONS  659 
 660 
This study provides one of the most in-depth qualitative and quantitative proteomics studies 661 
performed in ALS, using the plasma/PBMC interface to investigate crucial aspects of 662 
phenotypic heterogeneity of this condition and across species. Researchers working on ALS 663 
and on other neurodegenerative disorders will be able to draw on the data we have generated 664 
to steer the development of novel biomarkers and therapeutic strategies in ALS.  665 
 666 
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LIST OF ABBREVIATIONS  667 
ALS (amyotrophic lateral sclerosis) 
ALSFRS-R (amyotrophic lateral sclerosis Functional Rating Scale-
Revised) 
CRP (C-reactive protein) 
ECM (extracellular matrix) 
EDTA (Ethylenediaminetetraacetic acid) 
ER (Endoplasmatic Reticulum)  
FBS (Fetal bovine serum) 
FTD (frontotemporal dementia) 
HRP (horseradish peroxidase)  
IL (interleukin) 
ITGB3 (integrin Beta 3) 
LC-MS/MS (liquid chromatography tandem mass spectrometry) 
LIMMA (linear models for microarray data ) 
logFC (Log2 fold changes) 
MHC (major histocompatibility complex)  
NMJ (neuromuscular junction) 
PBMC  (peripheral Blood Mononuclear Cells) 
PBS (phosphate buffered saline) 
PCA (principal component analysis) 
PRL (disease progression to last visit ) 
PSM (peptide spectrum matches), 
RT (room temperature) 
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SASP (senescence-associated secretory phenotype) 
SCX (Strong Cation exchange) 
SOD1 (superoxide dismutase 1) 
TBST (tris buffered saline- tween) 
TCEP (tris (2-carboxyethyl) phosphine 10) 
TDP-43 (TAR DNA-binding protein 43) 
TEAB (triethylammonium bicarbonate) 
TGF-β1 (transforming growth factor beta 1) 
TMT (tandem mass tag) 
TNFα (tumor necrosis factor alpha)  
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 727 
Figure 1. Distribution of differentially regulated features and ALS patient phenotypic 728 
variants: (A) Principal component analysis (PCA) using scores plots before feature selection 729 
(colour codes: fast-early: yellow; fast-late: green; slow-early: red; slow-late: brown). The 730 
disease stage dimension is the main contributor to the separation in the first component 731 
(35.86%) and the rate of disease progression is the main contributor to the separation on the 732 
second component (15%). (B) PCA loadings plot generated with data derived from regulated 733 
features shows a more significant separation in the first compared to second component (40.6% 734 
and 17.5% respectively). (C) Volcano plot showing significantly regulated features comparing 735 
fast and slow progressing ALS patients in the early time point (cross-sectional study). (D) 736 
Volcano plot showing significantly regulated features comparing early and late time points for 737 
the slow progressing ALS patients (longitudinal study). Volcano plots agree with PCA showing 738 
a more significant difference between early and late time points when compared to fast versus 739 
slow disease progression.  740 
Figure 2. Functional analysis of the proteomic data obtained comparing data from fast 741 
versus slow progressing ALS patients.   742 
The cross-sectional analysis was based on the list of regulated proteins (FC 1.3, p value < 743 
0.05). Pathways with a p value < 0.05 were considered significantly enriched and–plotted 744 
with a -log 10 transformed p value. Functional analysis was performed for Reactome 745 
pathways, if not otherwise specified.  Only the pathways with the highest enrichment were 746 
reported among the selected redundant pathways (mostly cell cycle and mitosis (early) and 747 
RHO GTPase (late)). Significantly enriched pathways in the early stage (A), late stage (C) 748 
and in both time points (B).   749 
 750 
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Figure 3. Functional analysis of the proteomic data obtained comparing early versus late 751 
disease stage.  752 
The longitudinal analysis was undertaken using the list of total regulated proteins (FC 1.3, p 753 
value < 0.05) in slow and fast progressing ALS individuals independently. Pathways with a p 754 
value < 0.05 were considered significantly enriched and plotted with a - log 10 transformed p 755 
value in descending order of statistical significance. Functional analysis was performed for 756 
Reactome pathways, if not otherwise specified. Only pathways with the highest enrichment 757 
were reported among redundant pathways. Significantly enriched pathways in slow 758 
progressing patients (A), in fast progressing patients (C) and shared by slow and fast 759 
progressing patients (B). 760 
 761 
Figure 5. Re-test of protein candidates using immunoassays 762 
ELISA and Meso Scale Discovery (MSD) analysis of selected protein candidates in plasma 763 
samples. A. APOE is up-regulated in plasma samples from ALS-Fast compared to ALS-Slow; 764 
A1: positive correlation between APOE plasma levels and PRL in ALS patients; A2: reduced 765 
survival for ALS patient with higher APOE levels (above 70776 pg/ml). B. Galectin-3 is 766 
significantly downregulated in pre-symptomatic (Pre-SOD1129Sv) and fast in progressing 767 
SOD1G93A transgenic mice (Sym-SOD1129Sv) compared to 129Sv WT animals (WT129Sv). 768 
B1. TGFB1 is significantly downregulated in plasma from Pre-SOD1C57 and from Sym-769 
SOD1C57 compared to WTC57, while it upregulated up-regulated in Pre-SOD1129Sv and 770 
Sym-SOD1129Sv compared to WT129Sv. B2. ITGB3 is up-regulated in plasma from pre-771 
symptomatic transgenic SOD1G93 animal models (Pre-SOD1129Sv, Pre-SOD1C57) 772 
compared to related WT animals, while ITGB3 plasma expression in the respective 773 
symptomatic animals are significantly reduces to WT levels. In each figure, reported upper p-774 
values relate to Kruskall-Wallis while lower p-values to Dunn’s multiple comparisons tests. 775 
 36 
C. data mining using a RNA-Seq transcriptome and splicing database of glia, neurons, and 776 
vascular cells of the cerebral cortex. This interactive splicing browser shows predominant 777 
microglia expression of Galectin-3 (C), TGFB1(C1) and ITGB3 (C2) 778 
(https://web.stanford.edu/group/barres_lab/brain_rnaseq.html) in a range of cortical cells[28].  779 
PRL: progression rate to last visit. 780 
WT: wild type. 781 
OPC: oligodendrocyte precursor cells. 782 
FPKM: fragments per kilobase of transcript sequence per million mapped fragments. 783 
 784 
 785 
 786 
Figure 6. Human-animal model comparison of enriched pathways (A and C) and 787 
biological processes (B and D) derived from regulated proteins in each specie. (A) Shows 788 
the pathways and (B) the biological processes that were found enriched in both the mouse 789 
model pre-symptomatic stage and in the human ALS proteome at an early and a late disease 790 
stage respectively. (C) Shows the pathways and (D) the biological processes found enriched in 791 
both the mouse model symptomatic stage and the human ALS proteome at an early and late 792 
disease stage respectively. Pathways and biological processes, including translocation of 793 
GLUT4 to the plasma membrane or acute-phase response, that were found regulated in both 794 
mouse model and human plasma proteome at all time points are indicated with an asterisk (*). 795 
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 797 
 798 
 799 
 800 
 801 
 
Protein 
ID 
Protein Descriptions 
Gene 
Name 
Peptide 
# 
Early 
_Fast/Early 
Slow Log Fold 
Change 
adjusted 
p-value 
Up 
regulated 
in FAST. 
Early 
stage. 
P05106 Integrin beta-3 ITGB3 2 2.224407 0.001111 
O95810 
Serum deprivation-response 
protein 
SDPR 3 2.102 0.001403 
H7BYX
6 
Isoform of P13591, Neural cell 
adhesion molecule 1 
NCAM1 2 2.027403 0.000418 
P04003 
C4b-binding protein alpha 
chain 
C4BPA 7 2.013732 8.04E-05 
P07437 Tubulin beta chain TUBB 2 1.908567 0.00790 
P63173 60S ribosomal protein L38 RPL38 2 1.727873 0.00652 
Q14697 Neutral alpha-glucosidase AB GANAB 2 1.638215 0.00134 
P02649 Apolipoprotein E APOE 9 1.513701 8.53E-05 
P36957 
Dihydrolipoyllysine-residue 
succinyltransferase component 
of 2-oxoglutarate 
DLST 2 1.487187 0.00960 
 38 
dehydrogenase complex, 
mitochondrial 
A0A0A0
MR02 
Isoform of P45880, Voltage-
dependent anion-selective 
channel protein 2 
VDAC2 4 1.4397 0.00229 
P05090 Apolipoprotein D APOD 6 1.293627 0.00240 
P80723 Brain acid soluble protein 1 BASP1 4 1.220442 0.00111 
P15169 
Carboxypeptidase N catalytic 
chain 
CPN1 3 1.17725 0.00616 
Q06033-
2 
Isoform of Q06033, Isoform 2 
of Inter-alpha-trypsin inhibitor 
heavy chain H3 
ITIH3 4 1.176924 0.00172 
P48740-
2 
Isoform of P48740, Isoform 2 
of Mannan-binding lectin 
serine protease 1 
MASP1 2 1.126878 0.00134 
P35527 Keratin, type I cytoskeletal 9 KRT9 6 1.061453 0.00827 
Q15582 
Transforming growth factor-
beta-induced protein ig-h3 
TGFBI 3 1.026849 0.00652 
P07355 Annexin A2 ANXA2 6 1.021165 0.00788 
Down 
regulated 
in FAST 
Early 
stage. 
P69905 Hemoglobin subunit alpha HBA1 6 -1.12687 0.00682 
E7ETH0 
Isoform of P05156, 
Complement factor I 
CFI 3 -1.14553 0.00190 
O75636-
2 
Isoform of O75636, Isoform 2 
of Ficolin-3 
FCN3 4 -1.16238 0.00616 
Q96IY4 Carboxypeptidase B2 CPB2 2 -1.23801 0.00134 
 39 
P05452 Tetranectin CLEC3B 2 -1.32297 0.00173 
P30050 60S ribosomal protein L12 RPL12 2 -1.50426 0.00172 
P20700 Lamin-B1 LMNB1 2 -1.86089 0.00728 
P00505 
Aspartate aminotransferase, 
mitochondrial 
GOT2 2 -2.47293 0.00172 
P02042 Hemoglobin subunit delta HBD 3 -2.49876 0.00040 
Q5T123 
Isoform of Q9H299, SH3 
domain-binding glutamic acid-
rich-like protein 3 
SH3BGR
L3 
2 -2.75577 0.0011 
 802 
Table 2. Regulated proteins in fast compared to slow progressing ALS patients in the early 803 
disease stage. Only proteins identified with at least two unique peptides are shown. Up-804 
regulated proteins are shown in the upper part of the table (grey), with Integrin beta-3 showing 805 
the highest fold change. Down-regulated proteins are shown in the bottom part of the table 806 
(light blue), with Isoform of Q9H299, SH3 domain-binding glutamic acid-rich-like protein 3, 807 
showing the highest fold change of all down-regulated proteins. 808 
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